These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

495 related articles for article (PubMed ID: 30879102)

  • 1. Successful intra-class switching among IL-17 antagonists: a multicentre, multinational, retrospective study.
    Gasslitter I; Kirsten N; Augustin M; Torz K; Mrowietz U; Eyerich K; Puig L; Hoetzenecker W; Schütz-Bergmayr M; Weger W; Wolf P; Reider N; Ratzinger G; Papageorgiou K; Meier TO; Maul JT; Anzengruber F; Navarini AA
    Arch Dermatol Res; 2019 Jul; 311(5):421-424. PubMed ID: 30879102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasis.
    Bokor-Billmann T; Schäkel K
    J Dermatolog Treat; 2019 May; 30(3):216-220. PubMed ID: 30051725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL-17A Inhibitor Switching - Efficacy of Ixekizumab Following Secukinumab Failure. A Single-center Experience.
    Sherman S; Solomon Cohen E; Amitay-Laish I; Hodak E; Pavlovsky L
    Acta Derm Venereol; 2019 Jul; 99(9):769-773. PubMed ID: 31017250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term follow-up of 22 psoriatic patients treated with ixekizumab after failure of secukinumab.
    Amschler K; Phillip S; Mohr J; Wilsmann-Theis D; Poortinga S; Gerdes S; Mössner R
    Dermatol Online J; 2020 Jan; 26(1):. PubMed ID: 32155021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis.
    Bilal J; Berlinberg A; Bhattacharjee S; Trost J; Riaz IB; Kurtzman DJB
    J Dermatolog Treat; 2018 Sep; 29(6):569-578. PubMed ID: 29532693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of switches within the class of IL-17 inhibitors: An analysis of data from the Czech nationwide registry of psoriatic patients receiving biological/targeted therapy (BIOREP).
    Tichy M; Kojanova M; Velackova B; Dolezal T; Gkalpakiotis S; Cetkovska P;
    Dermatol Ther; 2022 Oct; 35(10):e15772. PubMed ID: 36065488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brodalumab in the treatment of moderate to severe psoriasis in patients when previous anti-interleukin 17A therapies have failed.
    Kimmel G; Chima M; Kim HJ; Bares J; Yao CJ; Singer G; Kim SJ; Bagel J; Lebwohl M
    J Am Acad Dermatol; 2019 Sep; 81(3):857-859. PubMed ID: 31078609
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3).
    Blauvelt A; Papp KA; Griffiths CEM; Puig L; Weisman J; Dutronc Y; Kerr LF; Ilo D; Mallbris L; Augustin M
    Am J Clin Dermatol; 2017 Apr; 18(2):273-280. PubMed ID: 28074446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world efficacy and safety of interleukin-17 inhibitors for psoriasis: A single-center experience.
    Ohata C; Ohyama B; Katayama E; Nakama T
    J Dermatol; 2020 Apr; 47(4):405-408. PubMed ID: 31994229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.
    Tada Y; Watanabe R; Noma H; Kanai Y; Nomura T; Kaneko K
    J Dermatol Sci; 2020 Jul; 99(1):53-61. PubMed ID: 32600737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-interleukin-17 therapies for moderate/severe psoriasis in clinical practice: effectiveness, safety and association with clinical patient factors.
    García-Martín E; Romero-Jiménez RM; Baniandrés-Rodríguez O; Escudero-Vilaplana V; Benedí-González J; de Los Ríos Luna PM; Herranz-Alonso A; Sanjurjo-Sáez M
    Eur J Hosp Pharm; 2024 Aug; 31(5):409-415. PubMed ID: 37094886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene: results from a multicentre study of four European psoriasis cohorts.
    van Vugt LJ; van den Reek JMPA; Meulewaeter E; Hakobjan M; Heddes N; Traks T; Kingo K; Galluzzo M; Talamonti M; Lambert J; Coenen MJH; de Jong EMGJ
    J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):112-118. PubMed ID: 31287604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ixekizumab for the treatment of psoriasis: up-to-date.
    Craig S; Warren RB
    Expert Opin Biol Ther; 2020 Jun; 20(6):549-557. PubMed ID: 32050819
    [No Abstract]   [Full Text] [Related]  

  • 14. Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study.
    Torres T; Puig L; Vender R; Lynde C; Piaserico S; Carrascosa JM; Gisondi P; Daudén E; Conrad C; Mendes-Bastos P; Ferreira P; Leite L; Lu JD; Valerio J; Bruni M; Messina F; Nidegger A; Llamas-Velasco M; Del Alcazar E; Mufti A; White K; Caldarola G; Teixeira L; Romanelli P; Desai K; Gkalpakiotis S; Romanelli M; Yeung J; Nogueira M; Chiricozzi A
    Am J Clin Dermatol; 2021 Jul; 22(4):567-579. PubMed ID: 33786754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changing within the same class: efficacy of brodalumab in plaque psoriasis after treatment with an IL-17A blocker - a retrospective multicenter study.
    Kromer C; Wilsmann-Theis D; Gerdes S; Krebs S; Pinter A; Philipp S; Mössner R
    J Dermatolog Treat; 2021 Dec; 32(8):878-882. PubMed ID: 32011917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-17 inhibitors for psoriasis.
    Paek SY; Frieder J; Kivelevitch D; Menter MA
    Semin Cutan Med Surg; 2018 Sep; 37(3):148-157. PubMed ID: 30215631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ixekizumab Effectiveness and Safety in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Multicenter, Retrospective Observational Study.
    Chiricozzi A; Burlando M; Caldarola G; Conti A; Damiani G; De Simone C; Dini V; Malagoli P; Peccerillo F; Potenza C; Scala E; Skroza N; Balato A
    Am J Clin Dermatol; 2020 Jun; 21(3):441-447. PubMed ID: 31786732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of IL-17 in the Pathogenesis of Psoriasis and Update on IL-17 Inhibitors for the Treatment of Plaque Psoriasis.
    AbuHilal M; Walsh S; Shear N
    J Cutan Med Surg; 2016 Nov; 20(6):509-516. PubMed ID: 27207350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical experience of ixekizumab in the treatment of patients with history of chronic erythrodermic psoriasis who failed secukinumab: a case series.
    Lo Y; Tsai TF
    Br J Dermatol; 2019 Nov; 181(5):1106-1107. PubMed ID: 31145806
    [No Abstract]   [Full Text] [Related]  

  • 20. Review of IL-17 inhibitors for psoriasis.
    Amin M; Darji K; No DJ; Bhutani T; Wu JJ
    J Dermatolog Treat; 2018 Jun; 29(4):347-352. PubMed ID: 29058501
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 25.